Verastem heads into its May 7 Q1 earnings print with a heavily-shorted register, a freshly-launched commercial campaign, and options traders swinging from bullish to cautious — all in the same month.
Short interest is the dominant structural story here. At 22.7% of the free float, the short position has barely moved in six weeks. It peaked near 24.8% in late March, drifted lower through April 10, then ticked back up this week — sitting now at a level the shorts seem content to hold. The FINRA fortnightly print confirmed roughly 17.4 million shares short as of April 15, with days to cover at nine. Nine days to cover is not a casual position; it represents a meaningful time commitment for any forced unwind. Yet borrow remains surprisingly cheap at 0.46% cost to borrow, and availability in the lending pool is wide open — a clear sign that despite 22% of the float being short, there is no supply squeeze underway. That's the key tension: a very large short base, but no sign of imminent pain.
Options positioning tells a more nuanced story. For most of April, put/call ratios were extraordinarily low — hugging 0.03-0.04, almost entirely call-dominated. That flipped sharply this week. The PCR jumped to 0.41, nearly ten times mid-month levels and more than 1.6 standard deviations above the 20-day mean of 0.15. The reading approaches the 52-week high of 1.65. Traders who were positioned almost entirely for upside through mid-April are now hedging meaningfully into the Q1 report. The timing of that shift — coinciding with the stock falling 11% this week to $5.40 — suggests the options market is getting cautious ahead of the print rather than expressing structural bearishness.
The Street remains constructively aligned, but not aggressively so. BTIG reiterated its Buy and $19 target twice in the past ten days, and HC Wainwright holds an $18 target. Jefferies assumed coverage in late March with a Buy but trimmed its target to $15 from $19 — the most notable recent nuance, suggesting Jefferies sees a path to upside but a narrower one than prior coverage. The mean price target of $16.38 against a $5.40 close implies an implied return of more than 200%, which is wide enough to reflect genuine clinical uncertainty rather than near-term conviction. Forward EPS momentum ranks in the 97th percentile for year-over-year growth — that likely reflects the base effect of a company with no near-term earnings, not a traditional growth beat cycle. EPS momentum over the trailing 30 days ranks in the 27th percentile, which is decidedly soft.
Institutional ownership adds an interesting layer. Several well-known specialist biotech funds built new positions in Q4 2025 and into Q1 2026. Deep Track Capital entered with 5.7 million shares. Foresite Capital, Nantahala, and Symbiosis all initiated or sharply increased positions in the same window. On the other side, Balyasny trimmed by roughly 950,000 shares. BlackRock and Vanguard added modestly in Q1 2026. The net picture from institutions is a cluster of specialist healthcare funds building exposure — these are not passive flows.
Insider selling has been consistent but in very small volumes. The CEO and CFO both sold shares in January and February, with the most recent CFO transaction in March involving just 57 shares. Trade significance scores are low across the board. These look like routine plan-based sales rather than conviction exits. There is no insider buying on the ledger to offset them, but the scale of selling is de minimis relative to the float.
The commercial catalyst worth watching is the freshly-launched "Reimagine" campaign for AVMAPKI FAKZYNJA CO-PACK — Verastem's approved combination targeting KRAS-mutated recurrent low-grade serous ovarian cancer. The campaign dropped today, April 30, directed at both physicians and patients. Execution data from initial commercial adoption will likely be the most watched metric in the May 7 Q1 call, with the short base closely monitoring whether early uptake justifies the current valuation. Previous earnings reactions have been mixed — the March 17 event produced a 4.3% one-day drop and a 15% five-day decline, while the March 4 event generated an 8.3% single-day gain. The distribution of those moves is wide, and the options market's new hedging posture appears to reflect exactly that uncertainty heading into next week.
See the live data behind this article on ORTEX.
Open VSTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
